Interactions of organic anion transporters and organic cation transporters with mycotoxins.
暂无分享,去创建一个
Toshiyuki Fukutomi | Kittipong Tachampa | H. Endou | N. Anzai | M. Tsuda | Naohiko Anzai | Suparat Khamdang | Hitoshi Endou | Toshiyuki Fukutomi | S. Sophasan | Michio Takeda | K. Tachampa | Rie Noshiro-Kofuji | Minoru Tsuda | Surawat Jariyawat | Samaisukh Sophasan | S. Jariyawat | M. Takeda | Suparat Khamdang | Rie Noshiro-Kofuji
[1] R. Phillips,et al. Effects of citrinin on renal function and structure. , 1980, Toxicology.
[2] S. Masuda,et al. Cellular and molecular aspects of drug transport in the kidney. , 2000, Kidney international.
[3] F. Lang,et al. Cloning and characterization of two human polyspecific organic cation transporters. , 1997, DNA and cell biology.
[4] G. You. The role of organic ion transporters in drug disposition: an update. , 2004, Current drug metabolism.
[5] H. Endou,et al. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. , 2001, European journal of pharmacology.
[6] A. Enomoto,et al. Role of human organic anion transporter 4 in the transport of ochratoxin A. , 2002, Biochimica et biophysica acta.
[7] D. Becroft,et al. Aflatoxins and Reye's disease. , 1972, British medical journal.
[8] I. Tamai,et al. Organic anion transporters. , 1999, Pharmaceutical biotechnology.
[9] Heinz Bönisch,et al. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3 , 2002, British journal of pharmacology.
[10] T. Massey,et al. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. , 1997, Molecular pharmacology.
[11] J. Kim,et al. Molecular Cloning and Characterization of Multispecific Organic Anion Transporter 4 Expressed in the Placenta* , 2000, The Journal of Biological Chemistry.
[12] A novel effect of bifemelane, a nootropic drug, on intracellular Ca2+ levels in rat cerebral astrocytes. , 2006, Journal of pharmacological sciences.
[13] H. Endou,et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. , 2002, Journal of Pharmacology and Experimental Therapeutics.
[14] P. Meier,et al. Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide. , 1996, The Journal of pharmacology and experimental therapeutics.
[15] G. Burckhardt,et al. Organic Anion Transporters of the SLC22 Family: Biopharmaceutical, Physiological, and Pathological Roles , 2007, Pharmaceutical Research.
[16] G. Burckhardt. Polyspecific Organic Cation Transport: Insights into the Substrate Binding Site , 2005, Molecular Pharmacology.
[17] Y. Kanai,et al. Cloning and Characterization of a Novel Multispecific Organic Anion Transporter * , 1997 .
[18] K. Giacomini,et al. Cloning and functional expression of a human liver organic cation transporter. , 1997, Molecular pharmacology.
[19] P. Mathur,et al. Study of an epidemic of jaundice, presumably due to toxic hepatitis, in Northwest India. , 1977, Gastroenterology.
[20] Y. Kanai,et al. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. , 1999, The American journal of physiology.
[21] Y. Kanai,et al. Organic anion transporter family: current knowledge. , 2006, Journal of pharmacological sciences.
[22] K. Jung,et al. Characterization of ochratoxin A transport by human organic anion transporters. , 2001, Life sciences.
[23] R. Hartley,et al. Toxicity and Fluorescence Properties of the Aflatoxins , 1963, Nature.
[24] Y. Kanai,et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. , 2001, Molecular pharmacology.
[25] D. Meijer,et al. Drug uptake systems in liver and kidney. , 2003, Current drug metabolism.
[26] A. Enomoto,et al. Interactions of Human Organic Anion Transporters and Human Organic Cation Transporters with Nonsteroidal Anti-Inflammatory Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.
[27] A. Enomoto,et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. , 2002, The Journal of pharmacology and experimental therapeutics.
[28] 楠原 洋之. 薬物トランスポーター, 膜輸送の基礎から薬物動態・生理的役割まで(7)腎臓, 脳(血液脳関門, 血液脳脊髄液関門)における有機アニオンの排泄メカニズムとしての Organic Anion Transporter (OAT) の役割(2) , 2003 .
[29] M. Obinata,et al. Cisplatin-induced toxicity in immortalized renal cell lines established from transgenic mice harboring temperature sensitive SV40 large T-antigen gene , 1996, Archives of Toxicology.
[30] Maristela L Onozato,et al. Expression of human organic anion transporters in the choroid plexus and their interactions with neurotransmitter metabolites. , 2003, Journal of pharmacological sciences.
[31] H. Kusuhara,et al. Molecular Cloning and Characterization of a New Multispecific Organic Anion Transporter from Rat Brain* , 1999, The Journal of Biological Chemistry.
[32] Y. Kanai,et al. Transport of ochratoxin A by renal multispecific organic anion transporter 1. , 1998, The Journal of pharmacology and experimental therapeutics.
[33] P. Howard,et al. Rat Kidney Pathology Induced by Chronic Exposure to Fumonisin B1 Includes Rare Variants of Renal Tubule Tumor , 2001, Toxicologic pathology.
[34] W. H. Butler,et al. Acute and chronic effects of aflatoxin on the liver of domestic and laboratory animals: a review. , 1969, Cancer research.
[35] J. Pitt. Toxigenic fungi and mycotoxins. , 2000, British medical bulletin.
[36] D. Keppler,et al. ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. , 2000, Kidney international.